tumor necrosis factor receptor

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]

Revdofilimab (ABBV-368) is a human IgG monoclonal antibody targeting Tumor Necrosis Factor Receptor superfamily member 4 (OX 40) with potential anticancer activity for the study of metastatic solid tumors and non-small cell lung cancer.

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

Afimkibart (PF06480605) is a humanised monoclonal antibody targeting TL1A (TNF-like Ligand 1A), which blocks TL1A-DR3 (death domain receptor 3) signalling on restrictive immune cells and fibroblasts. It can be used for inflammatory bowel disease and ulcerative colitis.

Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40, a type I transmembrane glycoprotein within the tumor necrosis factor receptor (TNFR) superfamily. CD40 functions as a costimulatory molecule, activating B cells, dendritic cells, monocytes, and other antigen-presenting cells (APC), thereby enhancing antitumor T cell responses.

TRX-518 is a humanized agonist antibody targeting the glucocorticoid-induced tumor necrosis factor receptor (GITR). It specifically targets GITR⁺ regulatory T cells (Tregs) and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) within regulatory T cells, effectively reducing the number of Tregs in circulation and within tumors.

Nesfrotamig is an immunoglobulin (H-γ1-scFv-L-κ) dimer humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig shows potential for use in ERBB2-positive tumor diseases, such as breast cancer and gastric cancer.

Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.

BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody that targets the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR). It binds to GITR and enhances the activation of T effector cells while deactivating T regulatory cells. BMS-986156 is applicable for research in advanced solid tumors.

HFB-200301 is an IgG1 antibody that targets the tumor necrosis factor receptor 2 (TNFR2). In the presence of sTNF, HFB-200301 enhances the activation of TNFR2, which then stimulates related signaling pathways, such as the activation of NF-κB dimers through the classical NF-κB pathway, influencing cell metabolism and gene expression. HFB-200301 shows potential for cancer research.

Cenzestotug is a monoclonal antibody targeting the human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). By binding to TNFRSF4, Cenzestotug activates associated immune cells, exerting immunostimulatory and anti-tumor effects. It shows potential for research in cancer immunotherapy.

Ramantamig is a humanized monoclonal antibody that targets human CD3ε, GPRC5D, and TNFRSF17 [tumor necrosis factor receptor superfamily member 17]. It holds potential for cancer research, particularly focusing on hematologic malignancies such as multiple myeloma.